Today's Information

Provided by: Tanvex BioPharma, Inc.
SEQ_NO 1 Date of announcement 2022/08/04 Time of announcement 16:05:00
Subject 
 The Company has been required by TWSE to announce
the financial data according to the regulations
Date of events 2022/08/04 To which item it meets paragraph 51
Statement 
1.Date of occurrence of the event:2022/08/04
2.Cause of occurrence:Request by TWSE to announce relevant information
3.Financial and business information:
Period             (Month)             (Quarter)        (Recent 4 quarter)
＝＝＝＝　   ＝＝＝＝＝＝＝＝＝＝  ＝＝＝＝＝＝＝＝＝＝　 ＝＝＝＝＝＝
Item         Previous month         Previous quarter　     2021 Q2~
             June 2022                  2022 Q1             2022 Q1
             (Financial Statement
             -Unaudited) YoY %                  YoY %
＝＝＝＝　   ＝＝＝＝　＝＝＝＝＝　＝＝＝＝＝ ＝＝＝＝＝  ＝＝＝＝＝＝
Revenue　　       1　        0           3  　     0　　        8
(Million)
Net Profit
before tax　　 (130)　   60.49%       (332)　  (20.00%)　　   (1,460)
(Million)
Net profit　　 (130)　   60.49%       (332)　  (20.00%)　　   (1,460)
(Million)
EPS　　        (0.37)　  41.85%       (0.94)　 (20.00%)　　    (4.35)
(dollar)
4.Any matters regarding to "Taiwan stock exchange corporation procedure for
  verification and disclosure of material information of companies with
  listed securities" article 4 that need to be specified:None.
5.Any matters regarding to "Taiwan stock exchange corporation procedure for
  verification and disclosure of material information of companies with
  listed securities" article 11 that need to be specified:None.
6.Please inquiry the items of financial Information on the website of MOPS,
and the paths as follow:
(1)Current sales revenue/income(loss):
Summaries>Financial Information applicable after adopting IFRSs
(2)Historic sales revenue per month:
Operating Statements>Monthly Sales Revenue>
Statement of Sales Revenue(after adopting IFRSs)
(3)Historic income or loss(audited/reviewed by the CPA):
Financial Statements>
FINANCIAL STATEMENT after adopting IFRSs>Balance Sheet/Income Statement
(4)Historic income or loss (self-assessed):
Operating Statements>Self-assessed income or loss:
7.Any other matters that need to be specified:None.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Tanvex Biopharma Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 08:16:01 UTC.